Compare Schwab US Dividend Equity ETF (SCHD) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Schwab US Dividend Equity ETF trades at $33.03 (market cap $110.56B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Schwab US Dividend Equity ETF is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Dividend Equity ETF for 62 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SCHD | TAK | |
|---|---|---|
Market Cap | $110.56B | $58.74B |
Volume | 23,539,168 | 3,110,994 |
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $19.05 |
52-Week Low | $26.44 | $13.23 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $33.09, up 1.35% with a bullish technical signal despite mixed moving averages. Recent news highlights its outperformance versus the S&P 500 in 2026 and dividend growth, though the ETF faces pressure from rising interest rates. Support sits at $32-$33, with resistance at $33-$34. The RSI readings are neutral, while ADX signals conflicting trend strength.
Outlook: SCHD offers income growth and lower fees, appealing for dividend investors, but interest rate sensitivity and defensive tilts pose risks. The ETF's rule-based approach may miss high-growth stocks, as seen with Broadcom. Near-term performance hinges on macroeconomic trends and dividend sustainability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
